Scholar Rock — Third Quarter 2026 Earnings Summary

Scholar Rock reported a net loss of $107.2 million for the third quarter of 2026, driven by the U.S. launch of ISEMBYLD, which generated $0.6 million in product revenue. The company holds $413.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and has entered a definitive agreement to sell a Priority Review Voucher for $205 million. Regulatory progress includes the FDA approval of ISEMBYLD for spinal muscular atrophy, a resubmitted Marketing Authorisation Application in Europe expected to yield a CHMP opinion in the first half of 2027, and a Japanese New Drug Application accepted for priority review.